-
Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen
•
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine space, has entered into a strategic collaboration with Germany’s Boehringer Ingelheim to advance the development of companion diagnostics (CDx). The partnership is aimed at identifying non-small cell lung cancer (NSCLC) patients who are most likely…
-
Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development
•
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN), focusing on the development of a companion diagnostic (CDx). This collaboration builds upon a global strategic master collaboration agreement that was first signed at the end of 2021.…
-
CIIE: MET HER2 Precision Diagnosis Alliance Formed to Advance Lung Cancer Treatment
•
The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision diagnosis alliance, a collaborative initiative involving AstraZeneca, Daiichi Sankyo, HutchMed, Roche Diagnostics, AmoyDx, LBP Medicine, Deep Informatics, Histo Medical Pathological Diagnosis Center, Rightongene Bio, and Genetron. This alliance aims to enhance the implementation of HER2…
-
BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development
•
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership with compatriot firm Amoy Diagnostics Co., Ltd (AmoyDx). The collaboration allows AmoyDx’s HER2 gene IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization) detection kits to support BeiGene’s filings for its drugs as companion diagnostics (CDx).…
